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Abstract
Background: Early identification of patients with drug-resistant tuberculosis (DR-TB) increases the likelihood of
treatment success and interrupts transmission. Resource-constrained settings use risk profiling to ration the use of
drug susceptibility testing (DST). Nevertheless, no studies have yet quantified how many patients with DR-TB this
strategy will miss.
Methods: A total of 1,545 subjects, who presented to Lima health centres with possible TB symptoms, completed a
clinic-epidemiological questionnaire and provided sputum samples for TB culture and DST. The proportion of drug
resistance in this population was calculated and the data was analysed to demonstrate the effect of rationing tests
to patients with multidrug-resistant TB (MDR-TB) risk factors on the number of tests needed and corresponding
proportion of missed patients with DR-TB.
Results: Overall, 147/1,545 (9.5 %) subjects had culture-positive TB, of which 32 (21.8 %) had DR-TB (MDR, 13.6 %;
isoniazid mono-resistant, 7.5 %; rifampicin mono-resistant, 0.7 %). A total of 553 subjects (35.8 %) reported one or
more MDR-TB risk factors; of these, 506 (91.5 %; 95 % CI, 88.9–93.7 %) did not have TB, 32/553 (5.8 %; 95 % CI, 3.4–8.1 %)
had drug-susceptible TB, and only 15/553 (2.7 %; 95 % CI, 1.5–4.4 %) had DR-TB. Rationing DST to those with an MDR-TB
risk factor would have missed more than half of the DR-TB population (17/32, 53.2 %; 95 % CI, 34.7–70.9).
Conclusions: Rationing DST based on known MDR-TB risk factors misses an unacceptable proportion of patients with
drug-resistance in settings with ongoing DR-TB transmission. Investment in diagnostic services to allow universal DST for
people with presumptive TB should be a high priority.
Keywords: Microscopic-observation drug-susceptibility assay, Multidrug-resistant tuberculosis, Tuberculosis, Drug
Susceptibility Testing
Background
Among notified patients with pulmonary tuberculosis
(TB) in 2014, the estimated total number of cases of
multidrug-resistant TB (MDR-TB) worldwide was
480,000, of which only approximately 123,000 were de-
tected [1]. The known MDR-TB epidemic represents the
tip of a dangerous iceberg, with unidentified patients
going on to develop advanced disease that is difficult
and expensive to treat, whilst at the same time transmit-
ting MDR-TB infection to their contacts and threatening
recent progress in global TB control.
Successful TB control programmes invite large
numbers of individuals with non-specific symptoms,
including cough, fever or weight loss, to attend their
local health facility for assessment to exclude TB. In
the case of MDR-TB disease, treatment outcomes are
best and most cost effective when patients receive
drug susceptibility testing (DST) at diagnosis [2].
However, providing baseline DST alongside TB diag-
nosis to all symptomatic individuals represents a huge
* Correspondence: martin.lauraj@gmail.com
1Laboratorio de Investigación de Enfermedades Infecciosas, Universidad
Peruana Cayetano Heredia, San Martín de Porras, Lima, Peru
2Section of Infectious Diseases & Immunity & Wellcome Trust Imperial
College Centre for Clinical Tropical Medicine, Imperial College London,
London, UK
Full list of author information is available at the end of the article
World TB Day
© 2016 Martin et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Martin et al. BMC Medicine  (2016) 14:30 
DOI 10.1186/s12916-016-0576-8
undertaking and many countries lack the capacity to
test all patients [1].
New diagnostic tests have been developed, include
Xpert MTB/RIF, which detects rifampicin resistance as a
marker for MDR-TB. This test is endorsed by the World
Health Organization (WHO) and has been implemented
in many resource-poor settings worldwide [1]. However,
the relatively high cost of the test means that, in settings
with constrained resources, it is suggested that only
individuals with MDR-TB risk factors are selected for
testing. The WHO Xpert implementation policy also
suggests that Xpert DST should be applied as the initial
diagnostic test in place of conventional microscopy, cul-
ture and DST in patients suspected of having MDR-TB
or HIV-associated TB [1].
This study was based in Lima, Peru, where MDR-TB
represents 3.9 % and 35 % of new and re-treatment TB
cases, respectively. In the course of a diagnostic evalu-
ation study [3], we collected detailed clinical, epidemio-
logical, microbiological and socioeconomic data from
patients who presented to government health centres for
TB investigations. This analysis investigates the hypoth-
esis that risk stratification to reduce the number of DSTs
performed results in a major failure in case detection of
drug-resistant TB (DR-TB).
Method
Study design, participants and settings
The study site, design and participants have been re-
ported previously [3]. Patients aged ≥18 years presenting
with respiratory symptoms and attending participating
TB clinics for the evaluation of possible TB were re-
cruited to the study after providing written informed
consent. At presentation, patients’ responses to a ques-
tionnaire were documented and two samples of sputum
were submitted to the National TB Programme for rou-
tine Ziehl–Neelsen smear followed by culture and DST.
Laboratory methods
Detection of Mycobacterium tuberculosis (MTB)
Sputum samples were decontaminated according to the
NaOH-NALC method [4]. Following this, an aliquot was
used for microscopic examination of auramine-stained
sputum smears and the remainder underwent parallel
TB culture on Löwenstein–Jensen medium and in
MODS liquid medium.
DST for rifampicin and isoniazid
Direct DST was performed with the MODS assay [5, 6].
Indirect DST was performed using the proportion
method [7] for isolates from the Löwenstein–Jensen cul-
ture (by an external laboratory) and with the automated
MBBacT system [8] for isolates from the automated
mycobacterial culture.
Field methods
Clinical, epidemiological and socioeconomic data were
collected using a standardized nurse-administered ques-
tionnaire. Data recorded included (1) the presence and
duration of symptoms; cough, expectoration, fever,
breathlessness, haemoptysis, weight loss, night sweats
and chest pain; (2) risk factor exposures for TB or DR-
TB, HIV infection, prior TB treatment, known TB or
MDR-TB contact, healthcare or prison service worker,
recent hospitalization or prison incarceration, drug and
alcohol use, or BCG vaccination; and (3) indicators of
household wealth related to income, education, over-
crowding and sanitation contributing to the “Necesidades
Basicas Insatisfechas”, a locally validated poverty score
described and used by the Economic Commission for
Latin America and the Caribbean [9].
Definitions
DR-TB was defined as strains of MTB resistant to rifam-
picin and/or isoniazid. Isoniazid mono-resistance was
defined as resistance to isoniazid by any method without
accompanying rifampicin resistance, rifampicin mono-
resistance was defined as resistance to rifampicin by any
method without accompanying isoniazid resistance, and
multidrug resistance was defined as resistance to both
rifampicin and isoniazid by any method [1]. The
remaining strains were defined as drug susceptible.
MDR-TB risk factors included previous TB treatment,
contact with a known MDR-TB patient, malabsorption,
exposure to environments with high rates of MDR-TB
(healthcare workers, prison workers and residents, previ-
ous hospitalisation) and HIV infection [10, 11].
Statistical analysis
Data were analysed using Stata 11 (College Station, TX:
StataCorp LP 2010). The principal outcomes of interest
were the proportion of DR-TB diagnosed among the
population of non-selected subjects and the proportion
of DR-TB diagnosed in subgroups of selected subjects
with and without MDR-TB risk factors. Subgroups con-
sidered were subjects with previous TB, contact with
MDR-TB, health workers, prison workers or residents,
and HIV infection (MDR-TB risk factors [10]), by all
subjects with any MDR-TB risk factor, and by smear
positive subjects only. Analyses were also performed
with and without inclusion of sputum smear results to
reflect the recommendation that rapid testing should be
used as the initial diagnostic test in adults with risk fac-
tors for MDR-TB in place of an initial sputum smear mi-
croscopy [1, 12]. The inclusion of the smear microscopy
result evaluated the sensitivity of using DST as a follow-
on test after initial smear microscopy.
The following calculations were undertaken for each
subgroup in which subjects would be selected for DST:
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(1) number of DSTs that would be performed, (2) num-
ber and proportion of DR-TB patients diagnosed, and
(3) number and proportion of DR-TB patients that
would be missed.
The number of subjects in each MDR-TB risk factor
subgroup were calculated to demonstrate the reduction
in burden of DSTs required should testing be restricted
to these subgroups.
Ethics review
Study protocol and consent forms were approved by
the institutional review boards of Universidad Peruana
Cayetano Heredia, Asociación Benéfica PRISMA,
Dirección de Salud–III Lima Norte and IV Lima Este,
Johns Hopkins Bloomberg School of Public Health,
and Imperial College London.
Results
Population characteristics
Pre-treatment sputum samples were provided by 1,545
patients who had presented for TB testing (40.2 % male,
mean age 36.1 years), of which 147 (9.5 %) were culture
positive for TB (50.3 % smear positive, Table 1). Drug
susceptibility testing identified 115 strains susceptible to
rifampicin and isoniazid (7.4 % of all samples and 78.2 %
of culture positive samples), 20 MDR strains (1.3 % of all
samples, 13.6 % of culture positive samples), 11 isoniazid
mono-resistant strains (0.7 % of all samples, 7.5 % of
culture positive samples), and one rifampicin mono-
resistant strain (0.1 % of all samples, 0.7 % of culture
positive samples). Overall, 520 subjects (33.7 %) met
criteria for living in poverty and 250 (16.2 %) for
overcrowding.
Factors associated with DR-TB diagnosis amongst
participants presenting for TB testing
Among the 1,545 participants, 553 (35.8 %) patients had
an MDR-TB risk factor (Table 2). Within this group, 47
(8.5 %) were sputum culture-positive for TB, 32 (2.1 %)
had TB sensitive to rifampicin and isoniazid, 11 (0.7 %)
had MDR-TB, four (0.3 %) had mono-resistant TB, 506
(91.5 %) were sputum culture-negative for TB, and 32
(2.1 %) had TB susceptible to rifampicin and isoniazid.
In total, 809 (52.3 %) patients reported prior TB con-
tact and 734 of these patients (90.7 %) had a negative
sputum culture; 161 subjects reported MDR-TB contact
(10.4 %) of whom 153 (95.0 %) had a negative sputum
culture, three had TB sensitive to rifampicin and isonia-
zid, three had MDR-TB, and two had mono-resistant
TB. One fifth of patients (n = 309) were previously
treated; 278 (90.0 %) were TB culture-negative and 12
(3.9 %) were diagnosed with DR-TB, representing 37.5 %
of DR-TB in this unselected study population. Health
workers accounted for 4.3 % of the population (n = 66),
and current or ex-prison workers/residents made up
2.5 % (n = 38). One subject in each of these groups was
diagnosed with DR-TB.
The impact of DST rationing upon numbers of patients
tested and DR-TB cases identified
If only those patients with a MDR-TB risk factor had
been selected for DST at diagnosis, 46.9 % (95 % CI,
29.6–64.2 %; n = 15) of patients with DR-TB (n = 32)
would have been detected.
Within the group of patients with DR-TB (n = 32),
43.8 % (95 % CI, 26.6–60.9 %; n = 14) were smear
positive; 42.9 % (five MDR-TB and one isoniazid mono-
resistant TB) of these smear positive patients with DR-
TB did not have any MDR-TB risk factors (Fig. 1).
Overall, 28 % (32/115) of patients with DR-TB had a
risk factor for MDR-TB whilst 36 % (506/1,398) of
patients who presented for TB testing but did not have
TB reported a risk factor for MDR-TB (Fig. 1).
If MDR-TB risk factors alone were used as criteria for
a DST at diagnosis, this would lead to 35.8 % (553/1,545;
95 % CI, 33.4–38.2 %) of patients being tested and
46.9 % (15/32; 95 % CI, 29.6–64.2 %) of DR-TB cases be-
ing detected; 64.2 % (992/1,545) of cases would not meet
the criteria for testing at the cost of missing 53.1 % (17/32;
95 % CI, 35.8–70.4 %) of DR-TB cases (Fig. 2, Table 3).
If MDR-TB risk factors and/or sputum smear positivity
together were used as criteria for a DST at diagnosis, this
would lead to 39.1 % (604/1,545; 95 % CI, 36.7–41.5 %)
of cases being tested and 65.6 % (21/32; 95 % CI, 49.2–
82.1) of DR-TB cases being detected; 60.9 % (941/1,545;
95 % CI, 58.5–63.3 %) would not meet the criteria for
testing at the cost of missing 34.4 % (11/32; 95 % CI,
17.9–50.8 %; Fig. 2, Table 3) of DR-TB cases.
If all patients were tested and all DR-TB cases identi-
fied, then 48 tests per DR-TB case identified would be
performed (Fig. 2, Table 3). This compares to 37 tests
per DR-TB case identified if MDR-TB risk factors alone
were used (albeit at a cost of 53.1 % of DR-TB cases
missed) and 29 tests per DR-TB case identified would be
performed if risk factors and/or smear positivity were
used (at a cost of 34.4 % missed DR-TB cases).
Discussion
The key finding of this work is that epidemiological risk
stratification to target DST testing and reduce testing
burden comes at too great a cost in MDR-TB cases over-
looked, regardless of the approach used.
Patient selection using WHO-defined risk factors for
MDR-TB [10] would consign 53.1 % (17/32) of patients
to a missed diagnosis of DR-TB in this population. Even
if patients with smear-positive sputum were also in-
cluded in a testing strategy, 34.4 % (11/32) of DR-TB
cases would be missed.
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Table 1 Study participant demographic, socioeconomic, epidemiological and clinical characteristics
All patients Sputum culture negative
for TB
Sputum culture positive for TB
Drug-susceptible TBa MDR-TB Mono-resistant TBa
N Unknown
(n)
n Unknown
(n)
n Unknown
(n)
n Unknown
(n)
n Unknown
(n)
Percentage
of all
subjects
Percentage
of all
patients
Percentage
of all
subjects
Percentage
of all
subjects
Percentage
of all patients
with drug
sensitive TB
Percentage
of all
subjects
Percentage
of patients
with MDR-TB
Percentage
of all
subjects
Percentage
of patients
with mono-
resistant TB
Number of
subjects
1,545 100.0 1,398 90.5 0 115 7.4 100.0 0 20 1.3 100.0 0 12 0.8 100.0 0
Age (mean) 36 0 37 0 32 0 32 0 32 0
Male sex 621 40.2 49.0 0 549 35.5 0 56 3.6 48.7 0 9 0.6 45.0 0 7 0.5 58.3 0
Smear positive 82 5.3 50.3 0 8 0.5 0 60 3.9 52.2 0 11 0.7 55.0 0 3 0.2 25.0 0
Povertyb 520 33.7 28.6 33 478 30.9 27 34 2.2 29.6 5 6 0.4 30.0 1 2 0.1 16.7 0
Overcrowdingc 250 16.2 15.0 20 228 14.8 16 14 0.9 12.2 4 7 0.5 35.0 0 1 0.1 8.3 0
TB contact 809 52.4 51.0 4 734 47.5 4 59 3.8 51.3 0 11 0.7 55.0 0 5 0.3 41.7 0
Smoker
(current/ex)
89 5.8 18.4 7 62 4.0 4 26 1.7 22.6 3 1 0.1 5.0 0 0 0.0 0.0 0
Drug user 23 1.5 4.1 3 17 1.1 3 6 0.4 5.2 0 0 0.0 0.0 0 0 0.0 0.0 0
Excess alcohol 185 12.0 19.7 3 156 10.1 3 25 1.6 21.7 0 3 0.2 15.0 0 1 0.1 8.3 0
Clinical information
Prior BCG
vaccine
1,338 86.6 90.5 21 1,205 78.0 21 105 6.8 91.3 0 18 1.2 90.0 0 10 0.6 83.3 0
Cough 1,290 83.5 87.1 1 1,162 75.2 1 101 6.5 87.8 0 17 1.1 85.0 0 10 0.6 83.3 0
Fever 514 33.3 47.6 5 444 28.7 4 50 3.2 43.5 1 14 0.9 70.0 0 6 0.4 50.0 0
Haemoptysis 238 15.4 31.3 5 192 12.4 5 41 2.7 35.7 0 3 0.2 15.0 0 2 0.1 16.7 0
Weight loss 754 48.8 69.4 8 652 42.2 8 80 5.2 69.6 0 15 1.0 75.0 0 7 0.5 58.3 0
Night sweats 567 36.7 49.0 8 495 32.0 7 54 3.5 47.0 1 12 0.8 60.0 0 6 0.4 50.0 0
Chest pain 940 60.8 66.7 7 842 54.5 7 77 5.0 67.0 0 12 0.8 60.0 0 9 0.6 75.0 0
Breathlessness 680 44.0 51.0 13 605 39.2 13 55 3.6 47.8 0 12 0.8 60.0 0 8 0.5 66.7 0
a Susceptible to isoniazid and rifampicin; 11 isoniazid mono-resistant, 1 rifampicin mono-resistant
b Participants with a socioeconomic score indicating poverty [9]
c Participants who meet criteria for overcrowding [9] if total household residents/number bedrooms >3.4
TB, Tuberculosis; MDR-TB, Multidrug-resistant tuberculosis
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Table 2 Study participant risk factors and microscopy and culture/drug-susceptible tuberculosis results
All subjects Sputum culture negative for TB Sputum culture positive for TB
Drug-susceptible TB MDR-TB Mono-resistant TB
Unknown
(n)
n Unknown
(n)
n Unknown
(n)
n Unknown
(n)n n Percentage
of all
subjects
Percentage
of all
subjects
Percentage
of all drug
sensitive TB
patients
Percentage
of all
subjects
Percentage
of all MDR-TB
patients
Percentage
of all
subjects
Percentage of all
mono-resistant
TB patients
All patients 1,545 1,398 90.5 0 115 7.4 100 0 20 1.3 100 0 12 0.8 100 0
≥1 MDR-TB-TB risk
factora
553 506 32.8 0 32 2.1 27.8 0 11 0.7 55.0 0 4 0.3 33.3 0
≥1 MDR-TB risk
factor or smear
Positive sputumb
604 509 32.9 0 74 4.8 64.3 0 16 1.0 80.0 0 5 0.3 41.7 0
Previous TB 309 278 18.0 4 20 1.3 17.4 0 8 0.5 40.0 0 3 0.2 25.0 0
Known contact
with MDR TB
161 153 9.9 8 3 0.2 2.6 0 3 0.2 15.0 0 2 0.1 16.7 0
Health worker 66 62 4.0 4 3 0.2 2.6 0 1 0.1 5.0 0 0 0.0 0.0 0
Current/ex prison
worker or resident
38 32 2.1 4 5 0.3 4.3 0 1 0.1 5.0 0 0 0.0 0.0 0
HIV infection 18 18 1.2 4 0 0.0 0.0 1 0 0.0 0.0 0 0 0.0 0.0 0
a MDR-TB risk factors as recommended by the WHO [10]; Previous TB treatment, Contact with known MDR-TBpatient), exposure to environments with high rates MDR TB (health care workers, prison workers & residents,
previous hospitalisation), HIV infection
bRepresents DST use as a follow on test after sputum microscopy
TB, Tuberculosis; MDR-TB, Multidrug-resistant tuberculosis
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This study suggests that epidemiological risk factors
for MDR-TB are neither sensitive nor specific for the
identification of patients with MDR or mono-resistant
TB; instead, MDR-TB risk factors are distributed among
all individuals that present for testing. Only 46.9 % of
patients diagnosed with DR-TB had a risk factor for
MDR-TB and a significant proportion of patients with
DR-TB or without culture-positive TB (27.8 % and
36.2 %, respectively) described a risk factor for MDR-TB
when they presented to the health centre.
There are strikingly low rates of MDR-TB disease
among ‘high risk’ groups despite this study recruiting an
unselected group of patients that attended for TB testing
in a TB endemic area. The large groups of current or ex-
healthcare workers and current or ex-prisoners or prison
workers yielded only a single patient with MDR-TB in
each group. Among the smear-positive patients who
were diagnosed with DR-TB disease, 42.9 % (6/14) did
not have a risk factor for MDR-TB. This group of infec-
tious smear-positive patients, five with MDR-TB and
one with isoniazid mono-resistant disease, would have
missed DST testing at presentation if only patients with
MDR-TB risk factors were selected for testing without
an initial sputum smear. This is a sobering finding since,
by the end of 2014, 69 % of countries reported following
national guidelines that recommend patients with risk
factors for MDR-TB undergo Xpert MTB/RIF as the ini-
tial diagnostic investigation [1, 12].
The repercussions of missed opportunities for early
diagnosis of active DR-TB are clear; unidentified DR-TB
patients progress to develop more severe disease, requir-
ing more prolonged and expensive treatment and have
worse outcomes than if the disease was correctly identi-
fied and treated at presentation [2, 13–16]. Unidentified
patients with DR-TB are more likely to infect contacts
than those on appropriate treatment. Viewed from an
economic perspective, this generates additional treat-
ment costs, estimated to lie within the range US$ 5,000–
10,000 per person with MDR-TB [1, 17, 18]. If drug
resistance were to progress to extensively DR-TB in pa-
tients with unidentified and untreated DR-TB, the esti-
mated cost of treatment rises to US$ 26,392 per person
[19]. These costs are likely to exceed funds saved by ra-
tioning initial DSTs to only those patients with MDR-TB
risk factors. This study demonstrates that using universal
rather than selective testing would have led to an
Fig. 1 Symptomatic patients with multidrug-resistant tuberculosis risk factors for each group
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increase in initial DST numbers required to 37–48 per
DR-TB case detected, a comparatively small expenditure
compared to costs of treating missed DR-TB patients.
A major strength of this study was its implementation
under real life conditions, recruiting a large number of
unselected patients who self-reported to government TB
program health centres and were able to provide detailed
clinical and socioeconomic information. The informa-
tion required to ascertain whether a patient would fulfil
WHO risk factors for MDR-TB criteria was obtained for
Fig. 2 Percentages of drug-resistant tuberculosis patients detected by testing strategies
Table 3 Performance of drug-susceptibility testing with risk stratification for detection of drug-resistant tuberculosis (DR-TB)
N Percentage of subjects
tested if only this
subgroup was selected
for drug-susceptibility
testing (95 % CI)
DR-TB cases
identified from
subgroup (n)
Percentage of DR-TB
cases identified
(95 % CI)
DR-TB cases
missed (n)
Percentage of
DR-TB cases
missed (95 % CI)
Numbers needed
to test to identify
one DR-TB case
All patients 1,545 100.0 32 100.0 0 0.0 48
Patient subgroups
≥1 MDR-TB risk factora 553 35.8 (33.4–38.2) 15 46.9 (29.6–64.2) 17 53.1 (35.8–70.4) 37
≥1 MDR-TB risk factor or
smear positive sputumb
604 39.1 (36.7–41.5) 21 65.6 (49.2–82.1) 11 34.4 (17.9–50.8) 29
Sputum smear positive 82 5.3 (4.2–6.4) 14 43.8 (26.6–60.9) 18 56.3 (39.1–73.4) 6
Previous TB 309 20.0 (18.0–22.0) 11 34.4 (17.9–50.8) 21 65.6 (49.2–97.0) 28
Known contact with
MDR-TB
161 10.4 (8.9–11.9) 5 15.6 (3.0–28.2) 27 84.4 (71.8–97.0) 32
Health worker 66 4.3 (3.3–5.3) 1 3.1 (0–9.2) 31 96.9 (90.8–100.0) 66
Current/ex prison
worker or resident
38 2.5 (1.7–3.2) 1 3.1 (0–9.2) 31 96.9 (90.8–100.0) 38
HIV infection 18 1.2 (0.6–107) 0 0 32 100.0 n/a
DR-TB, Drug-resistant tuberculosis; MDR-TB, Multidrug-resistant tuberculosis; CI, Confidence interval
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almost all patients. Patients were not asked specifically
about previous TB treatment in the private sector or
previous use of TB drugs of poor or unknown quality, as
is detailed in the WHO risk factor criteria; however,
these patients were likely to form a subset of the previ-
ously treated patients who were included as being at risk
of MDR-TB. We did not ask specifically about diseases
of malabsorption in this population, a pre-existing con-
dition that is considered to be a risk factor for MDR-TB,
though the attributable importance of this is likely to be
negligible. Arguably, a study limitation is that the 147
patients with TB (including 32 with DR-TB) constitute a
small proportion of the 1,545 individuals tested in this
study. However, it is precisely the scale of these propor-
tions that presents a real challenge for health systems
required to identify relatively small numbers of TB pa-
tients in large populations of symptomatic individuals.
The aim of targeting DST at diagnosis is to identify pa-
tients with DR-TB who would benefit from individua-
lised treatment. Patients with mono-resistant disease
were included in the analysis for this reason. Mono-
resistant disease risk factors distinct from MDR-TB risk
factors have not been identified, but are clinically likely
to overlap. The study was performed at a single site but
data are likely to be generalizable to settings where
MDR-TB transmission is established and MDR-TB is not
still restricted to patients with relapse [20].
The analysis reinforces findings from previous studies
that patient risk factors are unreliable for predicting who
will benefit from DST at diagnosis [21–25]. It raises im-
portant questions about true cost savings when DST is
limited to a relatively small subset of patients presenting
with possible TB symptoms.
Cost analyses have compared the Xpert MTB/RIF test
to conventional culture followed by DST [26, 27], but
not to rapid phenotypic culture methods [6, 28–30] that
could be sufficiently inexpensive to permit testing of all
patients presenting with suspected TB; therefore, a de-
tailed economic evaluation that includes these methods
would be valuable future work.
Preferential investment in laboratory infrastructure
would permit the provision of affordable universal
DST at diagnosis, as well as providing facilities for
confirmatory diagnostic testing, monitoring through-
out treatment and the development of second-line
drug resistance profiles for individualised treatment
regimes. Laboratory strengthening to provide these
important tools is an essential process so that a high
standard of care can be provided to all of the individ-
uals that require it.
Conclusions
Where resources are constrained, TB programmes are
forced to make choices about which patients should
undergo DST, despite the call from the WHO End TB
strategy for universal testing [31]. The unspoken ques-
tion is not “who can we afford to test?”, but rather “who
can we afford to not test?” The argument for universal
DST for TB patients is not complex: (1) early diagnosis
(and effective treatment) of DR-TB reduces morbidity
and interrupts transmission, (2) the cost of treating DR-
TB is extremely high, (3) the costs averted by preventing
secondary cases through earlier recognition and diagno-
sis of DR-TB are likely to outweigh the costs of testing,
(4) MDR-TB risk stratification is a blunt and inaccurate
tool, and (5) as shown here, the trade-off of targeted
testing is a systematic failure to detect all DR-TB for a
relatively trivial reduction in testing volume. Diagnostic
tests, such as Xpert MTB/RIF [12], Genotype MTB/DR
plus [32], MODS [3, 5] and the nitrate reductase
assay [28], which deliver direct DST at the same time
as making the TB diagnosis, go beyond asking “which
TB patients should be tested?” to “which patients
with presumptive TB should be tested?” If the goal of
global elimination is genuinely intended, surely the
only answer is “all”.
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